AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03111108
Drug: EBR/GZR (50 mg/100 mg) FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One FDC tablet taken once daily by mouth for 8 or 12 weeks depending upon randomization.
Trial: NCT03692026
Drug: Hyaluronic acid and Melatonin Mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a mixture of hyaluronic acid and melatonin will be prepared and added topically to the implant surface, extraction socket and peri-implant area for the study group
Trial: NCT00879372
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 12.5 mg TID
Trial: NCT03149445
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study medication will be administered for 91 days.
Trial: NCT06639152
Drug: oil-based contrast medium
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In oil group, ethiodized poppyseed oil (Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu Province, China, H20067895, iodine concentration of 480 mg/ml) was used as the contrast medium for hysterosalpingography.
Trial: NCT03654326
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching gefapixant tablet taken orally
Trial: NCT03654326
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium 275 mg tablets taken orally as needed, at dose prescribed by sites' principal investigator
Trial: NCT04113915
Drug: triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effect of treatment on immunity to obtain infection with hepatitis B\&C
Trial: NCT04113915
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral or parenteral steroid therapy for ITP
Trial: NCT00765375
Drug: Bacteriostatic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: .1 cc bacteriostatic saline/lesion
Trial: NCT05418426
Drug: Oral Reference
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: estradiol 1mg/progesterone 100 mg
Trial: NCT04008069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously
Trial: NCT00005775
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TrophAmine given any time that parenteral nutrition is required during the first 120 days of hospitalization.
Trial: NCT00005995
Drug: shark cartilage extract AE-941
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02489487
Drug: VM-1500
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VM-1500 40 mg
Trial: NCT00511199
Drug: NOMAC-E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomegestrol Acetate and Estradiol Tablets, 2.5 mg~NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
Trial: NCT00456365
Drug: pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg daily (subject age 8-12 years) or 40 mg daily (subject age 13-21 years)
Trial: NCT00456365
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily
Trial: NCT03442972
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03576820
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline pain score and associated migraine symptoms (such as nausea, vomiting, photophobia, and phonophobia) will be recorded for each subject. Subjects will then receive 0.9% sodium chloride solution via atomizer. Pain scores will be reassessed at 5, 10, and 20 minutes. Improvement in associated symptoms will be reassessed at 20 minutes.
Trial: NCT00679146
Drug: Thiocolchicoside+Ketoprofen
RxNorm normalized name: thiocolchicoside
DrugBank: Thiocolchicoside (DB11582)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet TCC 8 mg + ketoprofen 100 mg b.i.d + 2 tablets TCC placebo b.i.d
Trial: NCT01523574
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, given orally
Trial: NCT00070083
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00070083
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02510248
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match AL-704
Trial: NCT00855166
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for dapagliflozin, tablet, oral, once daily, 102 weeks
Trial: NCT01272258
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injection
Trial: NCT04160598
Drug: IV infusion
RxNorm normalized name: IV INFUSION SET (WINTHROP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Placebo Group): bolus 50 ml Nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate.
Trial: NCT04160598
Drug: intrathecal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-15mg hyperbaric bupivacaine and 30µg fentanyl intrathecally injected
Trial: NCT01767857
Drug: Xilonix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xilonix is a True Human Monoclonal Antibody targeting Interleukin 1 alpha, and is administered intravenously every 2 weeks with best supportive care until clinical or radiographic progression.
Trial: NCT01767857
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus best supportive care will be administered intravenously every 2 weeks until clinical or radiographic progression.
Trial: NCT01825863
Drug: Saline 9%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01514578
Drug: TRV130A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 1 hour duration
Trial: NCT04246749
Drug: [14C]-CRN00808
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug
Trial: NCT04246749
Drug: CRN00808
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug
Trial: NCT03173599
Drug: PNA 40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The beginning dose is 40mg.
Trial: NCT03173599
Drug: PNA 80mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The single dose is 80mg.
Trial: NCT03173599
Drug: PNA 160mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The single dose is 160mg.
Trial: NCT03173599
Drug: PNA 240mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The single dose is 240mg.
Trial: NCT03573089
Drug: Liberal phosphate target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All phosphate-lowering medications in use at baseline will be discontinued. Phosphate-lowering medications will be prescribed only if serum phosphate concentration exceeds 2.50 mmol/L. The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
Trial: NCT03573089
Drug: Intensive phosphate target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This will be achieved by prescribing phosphate-lowering medications aimed to intensively lower serum phosphate concentration towards normal level (≤1.50 mmol/L). The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
Trial: NCT04003142
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT03173599
Drug: PNA 360mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The single dose is 360mg.
Trial: NCT03173599
Drug: PNA 480mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The single dose is 480mg.
Trial: NCT03173599
Drug: PNA Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg.
Trial: NCT00059267
Drug: HBIG, Epivir, Hepsera
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00141193
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03376529
Drug: SPR741
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg IV over 1 hour
Trial: NCT00772525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: form: tablet~Route: oral
Trial: NCT02308254
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal administration
Trial: NCT01635530
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline: 100mg tablet two times per day, four weeks
Trial: NCT02489045
Drug: SHAPE measurement (Sonazoid ultrasoud contrast agent)
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
Trial: NCT03324412
Drug: Treatment of MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg， 3 times a day, oral, for 24 weeks.
Trial: NCT03324412
Drug: Treatment of MTX and TwHF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate : 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）：20mg， 3 times a day, oral, for 24 weeks.
Trial: NCT02465801
Drug: HSA-GCSF 1.2 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human Serum Albumin GCSF 1.2mg at day 3 and Day 7
Trial: NCT01603251
Drug: Artemether-lumefantrine combination
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-Lumefantrine (AL)combination; a placebo is given together with the first and fifth dose of AL
Trial: NCT02465801
Drug: HSA-GCSF 1.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human Serum Albumin GCSF 1.5 mg at day 3 and Day 7
Trial: NCT00966446
Drug: Unsupervised Decolonization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member.
Trial: NCT00795756
Drug: Triple intrathecal therapy (TIT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg. injected intrathecally x12 during induction/consolidation therapy
Trial: NCT00137423
Drug: SU011248 (sunitinib)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37.5 mg/day, oral, continuous daily dosing
Trial: NCT01928329
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00330616
Drug: 323U66 SR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00697203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po daily for 12 weeks
Trial: NCT00697203
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg po daily for 12 weeks
Trial: NCT00966446
Drug: Supervised Decolonization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member. In addition, households are contacted by study stuff via phone or text messages to ensure compliance, to provide reminders to household members to perform the decolonization protocol as well as to answer any question/concerns household members may have.
Trial: NCT03390686
Drug: HD204
RxNorm normalized name: Hydrocodone/Acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg IV every 3 weeks on Day 1
Trial: NCT02621411
Drug: Substance use
RxNorm normalized name: reSET Substance Use Disorder Therapy Software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are found use of substances by preoperative screen
Trial: NCT00114465
Drug: VSL#3
RxNorm normalized name: VSL#3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VSL#3 1 sachet twice a day
Trial: NCT00385515
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets to be dissolved in water for oral swish and expectorate; placebo, 4 times daily for 10 days
Trial: NCT05283057
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of placebo that is similar to Empagliflozin in physical appearance
Trial: NCT02735629
Drug: CX1739 - 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampakine CX1739 - 300 mg
Trial: NCT02735629
Drug: CX1739 - 600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CX1739 - 600 mg
Trial: NCT02735629
Drug: CX1739 - 900 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CX1739 - 900 mg
Trial: NCT02735629
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to 300 mg CX1739
Trial: NCT00003492
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT04993989
Drug: Iberogast (STW5, BAY98-7411)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survey without any intervention assigned in the study.
Trial: NCT01673451
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2006-matched placebo (Part A and Part B); Part B: dose level to be determined based on results of Part A, administered as capsules
Trial: NCT03350633
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine will be orally given at a dose of 2-3 mg/kg/d
Trial: NCT01333059
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01333059
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05451147
Drug: Chhinnavahni Kashaya Vati along with Agnimantha Kwatha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Chhinnavahni Kashaya Vati Form : Tablet Dose: 1g TDS (2x500 mg), Before meals Mode of Administration: Oral Anupaan: 20 ml of Agnimantha Kwatha Duration: 3 Months
Trial: NCT02733367
Drug: Infacort®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infacort® is a dry granule formulation of hydrocortisone stored in capsules available in different strengths (0.5, 1.0, 2.0 and 5.0 mg).
Trial: NCT01683955
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mL 0.9% sterile saline
Trial: NCT03150888
Drug: Antihypertensive Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or combination therapy with five type of antihypertensive agents, such as Ca channel blockers, ACE inhibitors, ARBs, diuretics, or beta-blockers.
Trial: NCT01133301
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During 3 weeks of the study, Placebo will be administrated (daily)
Trial: NCT01490476
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg per os / day or 05mg per os / day with 12 month
Trial: NCT01019642
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no active principles given.
Trial: NCT00004323
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004323
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01019174
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
Trial: NCT01500135
Drug: TachoSil®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TachoSil® is a sterile, ready-to-use, absorbable patch for intra-operative topical application. It consists of an equine collagen patch coated with fibrin glue components: human fibrinogen and human thrombin.
Trial: NCT01500135
Drug: Surgicel® Original
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgicel® Original is an absorbable hemostat (oxidized regenerated cellulose)
Trial: NCT00595075
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo identical in appearance to active experimental drug x 1 dose
Trial: NCT02167685
Drug: CMX001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02800746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline 100 ml is intravenously administered on 7-10 day before surgery
Trial: NCT01545310
Drug: SLV354
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of ABT-354
Trial: NCT00154245
Drug: Enteric-Coated Mycophenolate sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03715829
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03715829
Drug: PF06700841
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet taken QD
Trial: NCT00375739
Drug: PEP005
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00020176
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00721110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo boluses and infusions will be substituted
Trial: NCT00984750
Drug: acetyl-L-carnitine/statin (simvastatin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetyl-L-carnitine: 4 tablets of 500 mg a day~simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability
Trial: NCT00984750
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo: 4 tablets of 500 mg a day simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability
Trial: NCT01681849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
Trial: NCT02529956
Drug: UCB4940
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Active Substance: UCB4940~* Pharmaceutical Form: Solution for infusion~* Concentration: 80 mg/ml~* Route of Administration: Intravenous use
Trial: NCT01950039
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally in divided doses over 3 months
Trial: NCT04074837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo liquid suspension
Trial: NCT03338920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactose monohydrate powder administered via nosepiece
Trial: NCT01514422
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline 100 to 300mg per day for 8 weeks
Trial: NCT04203771
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen syrup at 20-30 mg/Kg of body weight, orally every 8 hours (t.i.d), for 7 days
Trial: NCT00003680
Drug: CMF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003680
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003680
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003680
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01813357
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: encapsulated tablet 20mg daily